Gastroenterology is the most prominent journal in the field of gastrointestinal disease. As the official journal of the American Gastroenterological Association, Gastroenterology delivers up-to-date, authoritative, clinically oriented coverage of all areas in gastroenterology. Regular features include articles by leading authorities, reports on the latest treatments for diseases, and an exclusive correspondence section. Gastroenterology is organized into the following sections to make material easy to find: Alimentary Tract; Liver, Pancreas and Biliary Tract; Case Reports; Special Reports and Reviews; and a section on Clinical Challenges which presents more in-depth information on how a diagnosis is reached. An additional feature is the Image of the Month.
Current impact factor: 16.72
Impact Factor Rankings
|2016 Impact Factor||Available summer 2017|
|2014 / 2015 Impact Factor||16.716|
|2013 Impact Factor||13.926|
|2012 Impact Factor||12.821|
|2011 Impact Factor||11.675|
|2010 Impact Factor||12.032|
|2009 Impact Factor||12.899|
|2008 Impact Factor||12.591|
|2007 Impact Factor||11.673|
|2006 Impact Factor||12.457|
|2005 Impact Factor||12.386|
|2004 Impact Factor||13.092|
|2003 Impact Factor||12.718|
|2002 Impact Factor||13.44|
|2001 Impact Factor||13.02|
|2000 Impact Factor||12.246|
|1999 Impact Factor||12.182|
|1998 Impact Factor||10.33|
|1997 Impact Factor||10.25|
|1996 Impact Factor||9.329|
|1995 Impact Factor||8.203|
|1994 Impact Factor||7.251|
|1993 Impact Factor||5.856|
|1992 Impact Factor||5.919|
Impact factor over time
|Other titles||Gastroenterology online., Gastroenterology|
|Material type||Periodical, Internet resource|
|Document type||Journal / Magazine / Newspaper, Internet Resource|
- Author can archive a pre-print version
- Author can archive a post-print version
- Pre-print allowed on any website or open access repository
- Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
- Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
- Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
- Set statement to accompany deposit
- Published source must be acknowledged
- Must link to journal home page or articles' DOI
- Publisher's version/PDF cannot be used
- Articles in some journals can be made Open Access on payment of additional charge
- NIH Authors articles will be submitted to PubMed Central after 12 months
- Authors who are required to deposit in subject-based repositories may also use Sponsorship Option
- Publisher last reviewed on 03/07/2015
- 'WB Saunders' is an imprint of 'Elsevier'
Publications in this journal
- [Show abstract] [Hide abstract]
ABSTRACT: Background & aims: The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis. Methods: We performed a multicenter, double-blind, parallel trial of 158 patients with cirrhosis receiving standard prophylaxis to prevent rebleeding (a β-blocker and band ligation) in Spain from October 2010 through October 2013. Within 10 days of bleeding, subjects were randomly assigned, but stratified by Child-Pugh scores of A or B vs C, to groups given simvastatin (20 mg/day the first 15 days, 40 mg/day thereafter; n=69) or placebo (n=78). Patients were followed for as long as 24 months. The primary endpoint was a composite of rebleeding and death, and main secondary endpoints were the individual components of the composite (death and rebleeding) RESULTS: The primary endpoint was met by 30/78 patients in the placebo group and 22/69 in the simvastatin group (P=.423). Seventeen patients in the placebo group died (22%) vs 6 patients in the simvastatin group (9%) (hazard ratio for adding simvastatin to therapy, 0.39; 95% confidence interval, 0.15-0.99; P=.030). Simvastatin did not increase survival of patients with Child-Pugh class C cirrhosis. Rebleeding occurred in 28% of patients in the placebo group and 25% in the simvastatin group (P=.583). Serious adverse events occurred in 53% of patients in the placebo group and 49% in the simvastatin group (P=.752); the percentages of serious adverse events related to therapy were 11% in the placebo group vs 8% in the in the simvastatin group (P=.599). Two patients in the simvastatin group, each with advanced liver disease, developed rhabdomyolysis. Conclusion: In a randomized controlled trial, addition of simvastatin to standard therapy did not reduce rebleeding but was associated with a survival benefit for patients with Child-Pugh class A or B cirrhosis. Survival was not the primary endpoint of the study, so these results require validation. The incidence of rhabdomyolisis in patients receiving 40 mg/day simvastatin was higher than expected. European Clinical Trial Database no: EUDRACT 2009-016500-24.
- [Show abstract] [Hide abstract]
ABSTRACT: Background & aims: The rs58542926 C>T variant of the transmembrane 6 superfamily member 2 gene (TM6SF2), encoding an E167K amino acid substitution, has been correlated with reduced total cholesterol (TC) and cardiovascular disease. However, little is known about the role of TM6SF2 in metabolism. We investigated the long-term effects of altered TM6SF2 levels in cholesterol metabolism. Methods: C57BL/6 mice (controls), mice that expressed TM6SF2 specifically in the liver, and mice with CRISPR/Cas9-mediated knockout of Tm6sf2 were fed chow or high-fat diets (HFD). Blood samples were collected from all mice and plasma levels of TC, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol, and triglycerides were measured. Liver tissues were collected and analyzed by histology, real-time PCR, and immunoblot assays. Adenovirus vectors were used to express transgenes in cultured Hep3B hepatocytes. Results: Liver-specific expression of TM6SF2 increased plasma levels of TC and LDL-c, compared with controls, and altered liver expression of genes that regulate cholesterol metabolism. Tm6sf2-knockout mice had decreased plasma levels of TC and LDL-c, compared with controls, and consistent changes expression of genes that regulate cholesterol metabolism. Expression of TM6SF2 promoted cholesterol biosynthesis in hepatocytes. Conclusions: TM6SF2 regulates cholesterol metabolism in mice and might be a therapeutic target for cardiovascular disease.
- [Show abstract] [Hide abstract]
ABSTRACT: Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to their optimal care. For individuals at risk for HCC, surveillance usually involves ultrasonography (there is controversy over use of biomarkers). A diagnosis of HCC is made based on findings from biopsy or imaging analyses. Molecular markers are not used in diagnosis or determination of prognosis and treatment for patients. The Barcelona Clinic Liver Cancer algorithm is the most widely used staging system. Patients with single liver tumors or as many as 3 nodules <3 cm are classified as having very early or early-stage cancer, and benefit from resection, transplantation, or ablation. Those with a greater tumor burden, confined to the liver, and are free of symptoms are considered to have intermediate-stage cancer, and can benefit from chemoembolization, if they still have liver function. Those with HCC symptoms and/or vascular invasion and/or extra-hepatic cancer are considered to have advanced-stage cancer and could benefit from treatment with the kinase inhibitor sorafenib. Patients with end-stage HCC have advanced liver disease that is not suitable for transplantation and/or have intense symptoms. Studies now aim to identify molecular markers and imaging techniques that can detect patients with HCC at earlier stages and better predict their survival time and response to treatment.
- [Show abstract] [Hide abstract]
ABSTRACT: Background & aims: Rectal indomethacin, a non-steroidal anti-inflammatory drug, is given to prevent pancreatitis in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), based on findings from clinical trials. European Society for Gastrointestinal Endoscopy guidelines recently recommended prophylactic rectal indomethacin for all patients undergoing ERCP, including those at average risk for pancreatitis. We performed a randomized controlled trail to investigate the efficacy of this approach. Methods: We performed a prospective, double-blind, placebo-controlled trial of 449 consecutive patients undergoing ERCP at Dartmouth Hitchcock Medical Center, from March 2013 through December 2014. Approximately 70% of the cohort were at average-risk for PEP. Subjects were randomly assigned to groups given either a single 100 mg dose of rectal indomethacin (n=223) or a placebo suppository (n=226) during the procedure. The primary outcome was the development of post-ERCP pancreatitis (PEP), defined by new upper-abdominal pain, a level of lipase greater than 3-fold the upper limit of normal, and hospitalization following ERCP for 2 consecutive nights. Results: There were no differences between the groups in baseline clinical or procedural characteristics. Sixteen patients in the indomethacin group (7.2%) and 11 in the placebo group (4.9%) developed PEP (P=.33). Complications and the severity of PEP were similar between groups. Per a priori protocol guidelines, the study was stopped due to futility. Conclusions: In a randomized controlled study of consecutive patients undergoing ERCP, rectal indomethacin did not prevent post-ERCP pancreatitis. ClincialTrials.gov no: NCT01774604.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.